INTEGRA Biosciences announced strong end of year sales of over Euro 5 million
Well positioned for growth in 2004
INTEGRA Biosciences (Chur, Switzerland), a specialist supplier of innovative products for microbiology and cell culture laboratories, has announced strong end of year sales of over Euro 5 million.
Have achieved a series of notable changes enabling the business to move strongly forward in 2003, INTEGRA Biosciences has announced a range of investments that will position the company for growth again in 2004. Notable amongst the investments are increased spending on new product development (> 12%), further development of worldwide sales channels and expanded facilities for R&D and Sales & Marketing at the Swiss headquarters.
Reflecting upon the past year, Elmar Morscher (Managing Director) commented 'completing our reorganisation has enabled us to focus resources to better serve our customers worldwide - almost all major territories have shown positive development of business levels'. He added 'listening to the needs of our customers we introduced the PIPETBOY Comfort, VACUSAFE Comfort and CELLine adhere in 2003 - these high quality products already account for 18% of our turnover'.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Evotec and Centogene sign partnership on drug discovery projects in rare genetic diseases

Newly developed, bioinspired cell delivery vehicles

3-D bioprinted human cartilage cells can be implanted
Novartis announces typhoid vaccine research program in partnership with the Wellcome Trust - New grant from the Wellcome Trust funds progression of vaccine from preclinical through Phase I and II studies with view to protect against both S. Typhi and S. Paratyphi strains

Merck Reports Strong Third Quarter - In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion
Breakthrough: Gut bacteria drive growth of stem cells in colon cancer
